RxDoctor Payments Data

Marvin Rossi, MD

Neurology · Chicago, ILNPI 1275529091

Payments from drug & device makers

$186,703in general payments, 2019–2025

Across 136 payments — averaging $1372.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Upsher-smith Laboratories LLC$67K
  • Eisai Inc.$37K
  • SK Life Science, Inc.$36K
  • UCB, Inc.$15K
  • Neuropace, Inc.$14K
  • Livanova USA, Inc.$9K
  • plus $8K from 8 others

What the payments were for

  • Consulting fees$12,79018%
  • Speaking & faculty fees$53,57474%
  • Travel & lodging$1,6412%
  • Food & beverage$4,5876%
  • Education$820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$186,703 in reported general payments places this provider in the 90th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$73,479
Medicare patients
200
Services billed
633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)56$255,295
XcopriCenobamate95$147,096
BriviactBrivaracetam79$110,981
OnfiClobazam35$72,219
ValtocoDiazepam30$27,726
Lacosamide265$27,721
VimpatLacosamide26$24,278
Lamictal XrLamotrigine12$17,831
FycompaPerampanel16$15,229
Clobazam54$5,596
Levetiracetam150$5,197
DilantinPhenytoin Sodium Extended34$4,518
Oxcarbazepine28$3,141
Carbamazepine15$1,859
Divalproex Sodium ErDivalproex Sodium34$1,661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$36,244$147,09695 claims
UCB, Inc.Briviact, Vimpat$15,319$135,259105 claims
Neurelis, Inc.Valtoco$59$27,72630 claims
Eisai Inc.Fycompa$36,976$15,22916 claims
Upsher-smith Laboratories LLCTopiramate$67,460$49634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 790 neurology providers in Illinois.

Other neurology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →